ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

Åãͬ×ÅCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÁÆ·¨µÄÉú³¤£¬£¬£¬£¬£¬£¬£¬£¬ÏÖÔÚѪҺÖ×ÁöÒѾ­²»ÔÙÊÇÎÞ½âµÄÄÑÌ⣬£¬£¬£¬£¬£¬£¬£¬ÏÖÔÚÒѾ­ÓжàÖÖCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÁÆ·¨¿ÉÒÔÔÚѪҺÖ×ÁöµÄÖÎÁÆÖеִï90%ÒÔÉϵĿ͹ۻº½âÂÊ£¬£¬£¬£¬£¬£¬£¬£¬²¢ÇÒ´Óºã¾ÃµÄÖÎÁÆÊý¾ÝÀ´¿´£¬£¬£¬£¬£¬£¬£¬£¬»¼Õß×ÜÌåÉúÑÄÂÊÒ²¿ÉÒÔµÖ´ï44%£¨4ÄêÉúÑÄÆÚ£©£¬£¬£¬£¬£¬£¬£¬£¬Í¬Ê±×ÝÈ»ÊÇÖ×Áö¸´·¢ÁË£¬£¬£¬£¬£¬£¬£¬£¬Ò²¿ÉÒÔÔٴνÓÊÜCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖÎÁÆ£¬£¬£¬£¬£¬£¬£¬£¬ÕâÒâζ×ÅCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÁÆ·¨ÒѾ­´ó´ó½µµÍÁËѪҺÖ×ÁöµÄΣº¦¡£¡£¡£¡£¡£¡£¡£¡£

CAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¹¥»÷Ö×ÁöÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¨Í¼Æ¬ÈªÔ´£ºÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£©

¿ÉÊÇÕûÌåÀ´Ëµ£¬£¬£¬£¬£¬£¬£¬£¬ÑªÒºÖ×ÁöÕ¼±ÈÔÚËùÓÐÖ×ÁöÖв¢²»¸ß£¬£¬£¬£¬£¬£¬£¬£¬´ó´ó¶¼Ö×Áö»¼Õ߶¼ÊÇʵÌåÁö¡£¡£¡£¡£¡£¡£¡£¡£ÒÔÊÇ£¬£¬£¬£¬£¬£¬£¬£¬CAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÊÇ·ñÄÜÓÐÓõع¥¿ËʵÌåÖ×Áö²ÅÊÇÖ×ÁöÃâÒßÖÎÁƵÄÒªº¦¡£¡£¡£¡£¡£¡£¡£¡£¹¥¿ËʵÌåÖ×Áö×î½¹µãµÄÎÊÌâÊÇÕÒµ½ÌØÒìÐԵİеãÏ¢Õù³ýÖ×Áö΢ÇéÐιØÓÚCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾µÄÃâÒßÒÖÖÆ£¬£¬£¬£¬£¬£¬£¬£¬ÄÇôµ½ÕâÀïÎÒÃǾͲ»µÃ²»Ìáµ½PD-1/PD-L1×÷ÓÃÖá——ËüÃÇÕýÊÇÖ÷Ô×Ö×ÁöÒýÆðTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÃâÒßÒÖÖƵÄÖ÷Ҫ;¾¶¡£¡£¡£¡£¡£¡£¡£¡£

ÓëCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÁÆ·¨²î±ðµÄÊÇ£¬£¬£¬£¬£¬£¬£¬£¬ PD-1/PD-L1ÒÖÖƼÁµÄ×÷ÓûúÖÆÊÇ×è¶ÏPD-1ÓëPD-L1µÄÏ໥×÷Ó㬣¬£¬£¬£¬£¬£¬£¬´Ó¶øɨ³ýÀ´×ÔÖ×ÁöµÄPD-L1¶ÔTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾µÄÒÖÖÆ¡£¡£¡£¡£¡£¡£¡£¡£¿ÉÊÇÕâЩÒÖÖƼÁÊÇ·ñÄܽøÈëÖ×Áö΢ÇéÐÎÊ©Õ¹×÷ÓÃÊÇÆäÖÎÁƳɰܵÄÒªº¦£¬£¬£¬£¬£¬£¬£¬£¬¶ø¸ßŨ¶È»òÍŽáÓ¦ÓÃÓֻᵼÖÂÈ«ÉíµÄ¸±×÷ÓÃÔöÌí¡£¡£¡£¡£¡£¡£¡£¡£ÊÇ·ñ¿ÉʹÓñí´ïPD-1¿¹ÌåµÄCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬£¬£¬£¬£¬£¬ÒÔʵÏÖPD-1¿¹ÌåÔÚ¾Ö²¿ÐγɸßŨ¶È£¬£¬£¬£¬£¬£¬£¬£¬¶øɨ³ýÖ×Áö΢ÇéÐÎÒÖÖÆÄØ£¿£¿£¿£¿£¿

2ÔÂ18ÈÕ£¬£¬£¬£¬£¬£¬£¬£¬¡¶BMJ¡·£¨¡¶Ó¢¹úÒ½Ò©ÔÓÖ¾¡·£©ÆìϵĹú¼ÊÒ»Á÷ѧÊõÆÚ¿¯¡¶Journal for ImmunoTherapy of Cancer¡·£¨¡¶°©Ö¢ÃâÒßÖÎÁÆÔÓÖ¾¡·£©£¨IF=10.252£©ÔÓÖ¾ÉϽÒÏþµÄÎÊÌâÃûΪ“αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib”ÁÙ´²°¸Àý±¨¸æ£¬£¬£¬£¬£¬£¬£¬£¬»Ø¸²ÁËÕâÒ»ÎÊÌâ¡£¡£¡£¡£¡£¡£¡£¡£

ͼƬȪԴ£º¡¶Journal for ImmunoTherapy of Cancer¡·¹ÙÍø

¸ÃƪÎÄÕÂÒ²Êǹú¼ÊÉϵÚһƪ¹ØÓÚÓÃCAR-T×ÔÉø͸PD-1¿¹ÌåÖÎÁÆʵÌåÖ×ÁöµÄÁÙ´²ÎÄÕ£¬£¬£¬£¬£¬£¬£¬£¬Í¬Ê±Ò²ÊÇÉϺ£ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖÎÁÆÍŶӴòÔìµÄ°×ÔóTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖÎÁÆÊÖÒÕÊ×´ÎÔÚʵÌåÖ×ÁöÁÙ´²»ñµÃÏÔ×ÅÁÆЧµÄ°¸Àý¡£¡£¡£¡£¡£¡£¡£¡£

½ÓÊÜÖÎÁƵÄÊÇÒ»Ãû54ËêµÄÍíÆÚÂѳ²½¬ÒºÐÔÏÙ°©Å®ÐÔ»¼Õߣ¬£¬£¬£¬£¬£¬£¬£¬ÔÚÇ°ÆÚµÄÃâÒßѧ¼ì²éÊý¾ÝÖÐÏÔʾ£º

ÑôÐÔµÄÖ¸±êÓУºCK7(+), CA125(+), WT-1(+), EMA(+), CAM5.2 (+), ER(+), PR(+++), calretinin (partial +), p53(+++), Ki67(60%), CD34(blood vessel +)£»£»£»£»£»£»£»

ÒõÐÔÖ¸±êΪ£ºHer2, CK20, CA19-9, ²¨ÐÎÂÑ°×, CEA, and HBME-1¡£¡£¡£¡£¡£¡£¡£¡£

»¼ÕßÊ×ÏȽÓÊÜ×Ïɼ´¼ÍŽá˳²¬»¯ÁÆ£¬£¬£¬£¬£¬£¬£¬£¬¹²8´Î¡£¡£¡£¡£¡£¡£¡£¡£ºó¾­¼ªÎ÷Ëû±õ¼Ó°ÂɳÀû²¬ËĸöÖÜÆÚÖÎÁÆ£¬£¬£¬£¬£¬£¬£¬£¬Ê¹¼²²¡Îȹ̡£¡£¡£¡£¡£¡£¡£¡£È»¶øµ½2017Äê8Ô£¬£¬£¬£¬£¬£¬£¬£¬¸Î²¿·ºÆðÐÂС²¡±ä£¬£¬£¬£¬£¬£¬£¬£¬µ«2018Äê3Ô²¡±äÀ©´ó£¬£¬£¬£¬£¬£¬£¬£¬Ëæ½ÓÊÜ°¢ÅÁÌæÄáÖÎÁƺ󼲲¡ÔÙ´ÎÎȹ̡£¡£¡£¡£¡£¡£¡£¡£2018Äê10ÔÂÖ×Áö¸´·¢Ê±£¬£¬£¬£¬£¬£¬£¬£¬¾­ÓÉÃâÒßѧ¼ì²éÆÀ¹À£¬£¬£¬£¬£¬£¬£¬£¬»¼ÕßתÒÆÔîºÍÔ­·¢Ôî¾ù±í´ï¼äƤËØ£¬£¬£¬£¬£¬£¬£¬£¬ÇкÏÈë×éÌõ¼þ£¬£¬£¬£¬£¬£¬£¬£¬»¼ÕßÇ©ÊðÖªÇéÔÞ³ÉÊéºóÓÚ2018Äê12Ô½ÓÊÜPD-1-meso CAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Ê×´ÎÖÎÁÆ£¬£¬£¬£¬£¬£¬£¬£¬2019Äê1Ô½ÓÊܵڶþ´ÎÊä×¢¡£¡£¡£¡£¡£¡£¡£¡£

»¼Õß½ÓÊÜÖÎÁÆÖÜÆÚ¼°Ó°Ïñѧ×ÊÁϱÈÕÕ£¬£¬£¬£¬£¬£¬£¬£¬¿É¼ûÖÎÁƺóÖ×ÁöÏÔ×ÅËõС£¡£¡£¡£¡£¡£¡£¡£¨Í¼Æ¬ÈªÔ´£º²Î¿¼×ÊÁÏ1£©

±¾´ÎʹÓõÄCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Ô­ÖÊÁÏȪԴÓÚ»¼Õß×ÔÉíµÄTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬£¬£¬£¬£¬£¬ÔÚÖƱ¸Àú³ÌÖÐʹÓõÄÊǷDz¡¶¾ÔØÌåÖƱ¸ÊÖÒÕ¡£¡£¡£¡£¡£¡£¡£¡£»£»£»£»£»£»£»ØÊäPD-1-meso CAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ºó£¬£¬£¬£¬£¬£¬£¬£¬»¼ÕßѪҺ²»µ«CAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÊýÄ¿»ñµÃÁËÀ©Ôö£¬£¬£¬£¬£¬£¬£¬£¬²¢ÇÒ×ÔÉíµÄCD8+TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾µÄ»îÐÔÒ²»ñµÃÁËÔöÇ¿£¬£¬£¬£¬£¬£¬£¬£¬ÕâÅú×¢»ØÊä½øÈËÌåµÄCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÒѾ­×îÏÈ·¢Æôº½ÌåÄÚµÄÃâÒßÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøվΧ½ËÖ×ÁöÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬£¬£¬£¬£¬£¬´Ó¶øÊ©Õ¹¸üºÃµÄ¿¹Ö×ÁöЧ¹û¡£¡£¡£¡£¡£¡£¡£¡£

ÍŽáÁÆ·¨µÄCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖƱ¸¡¢»ØÊäºÍ¼ì²âʱ¼ä±í¡¢PD-1¿¹ÌåÒÔ¼°ÌåÄÚÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Òò×ÓÖÎÁÆÇ°ºóת±ä£¨Í¼Æ¬ÈªÔ´£º²Î¿¼×ÊÁÏ1£©

ÔÚÒÔÍùµÄÖÎÁÆÇéÐÎÖУ¬£¬£¬£¬£¬£¬£¬£¬ÃâÒß×éºÏËäÈ»»áÔöÌíÖÎÁÆЧ¹û£¬£¬£¬£¬£¬£¬£¬£¬¿ÉÊÇÒ²»áÔöÇ¿ÖÎÁƵĸ±×÷Ó㬣¬£¬£¬£¬£¬£¬£¬ÄÇôCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾×ÔÉø͸PD-1¿¹ÌåÊÇ·ñ»áÔöÌí¸±×÷Óõı¬·¢ÄØ£¿£¿£¿£¿£¿

±¾°¸Àý¼°ÆäËûÉÐ䱨µÀµÄ°¸Àý·¢Ã÷£¬£¬£¬£¬£¬£¬£¬£¬ÕâÖֶ๦ЧCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾²¢Ã»ÓÐÒýÆðµÄÏÔ×ŵIJ»Á¼·´Ó¦£¬£¬£¬£¬£¬£¬£¬£¬½ö·ºÆðÁ˸ßѪѹ1¼¶ºÍ·¦Á¦µÈÉÔ΢µÄ¸±×÷Óᣡ£¡£¡£¡£¡£¡£¡£ÎÒÃÇÍƲâPD-1¿¹Ìå¿ÉÄÜÍ£ÁôÔÚCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾°ÐÏòºÍÀ©ÔöµÄµØ·½£¬£¬£¬£¬£¬£¬£¬£¬Ð§¹û²»»áÔì³ÉÑÏÖز»Á¼·´Ó¦¡£¡£¡£¡£¡£¡£¡£¡£

±¾´ÎµÄÖÎÁÆ°¸Àý£¬£¬£¬£¬£¬£¬£¬£¬¸ü¾ßÓÐÒâÒåµÄÒ»µãÊǸ¶ÓëÁËCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¸ü¶àµÄ¹¦Ð§£º´Ó½ö½öÓÃÓÚ°ÐÏòɱÉËÖ×ÁöÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬£¬£¬£¬£¬£¬Äð³ÉÁË¿ÉÒÔЯ´ø¶àÖÖ¿¹Ìå´Ó¶ø¸Ä±äÖ×Áö΢ÇéÐβ¢¼¤»îÌåÄÚÔ­ÓеÄÃâÒßÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬£¬£¬£¬£¬£¬ÅäºÏ¶Ô¿¹Ö×Áö£¬£¬£¬£¬£¬£¬£¬£¬ÌåÏÖÁË“Ö×Áö¾Ö²¿É±ÉË+ÐÞ¸´Ö×Áö¾Ö²¿ÃâÒß·´Ó¦”£¬£¬£¬£¬£¬£¬£¬£¬´Ó¶ø¸üºÃ¡¢¸ü³¤ÆÚµÄÊ©Õ¹¿¹Ö×Áö×÷Óᣡ£¡£¡£¡£¡£¡£¡£